Details:
ORY-4001 is a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological diseases as Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS).
Lead Product(s): ORY-4001
Therapeutic Area: Genetic Disease Product Name: ORY-4001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Proceeds will be used to fund the FIGHT-DM 1 project to initiate clinical trial of Arthex' lead candidate, ATX-01, in DM1 in 2023.
Lead Product(s): ATX-01
Therapeutic Area: Genetic Disease Product Name: ATX-01
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: EIC Accelerator
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 25, 2022
Details:
Under this collaboration, CMTRF will be financing a series of in vivo tests with Oryzon’s HDAC6 candidates in a murine model of CMT1A, which reliably recapitulates many of the symptoms of this condition in humans.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: CMT Research Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 26, 2022
Details:
This agreement follows the completion of research agreement, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular dystrophy identified using SOM Biotech’s platform, SOMAIPRO.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Minnesota
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 17, 2022
Details:
Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects.
Lead Product(s): Vafidemstat
Therapeutic Area: Genetic Disease Product Name: ORY-2001
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Kennedy Krieger Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 03, 2022